🇺🇸 FDA

Company profile · Sponsor

Dompe'

Dompe' Farmaceutici S.p.A.

E24D8D7 · EMA pharma EU
Pipeline
11
Drugs
0
Patents
0

Quick answer

Dompe' (E24D8D7) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E24D8D7
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (11)

Search pipeline →

  1. Placebo (Vehicle) for investigational DFL24498, Isocyclosporin A, DEXAMETHASONE

    Dompe'

    Atopic Keratoconjunctivitis

    phase 3 small molecule active

    1 trial

  2. TROPICAMIDE, Vehicle for cenegermin drug product, COLIROFTA ANESTÉSICO DOBLE 1 MG/ML + 4 MG/ML COLIRIO EN SOLUCIÓN, OXERVATE 20 micrograms/ml eye drops, solution

    Dompe'

    Persistent Corneal Epithelial Defect (PCED)

    phase 3 small molecule active

    1 trial

  3. Cenegermin, The placebo for investigational lyophilized cenegermin Drug Product is the same as the Drug Product with the exception that it does not contain cenegermin.

    Dompe'

    Spastic Cerebral Palsy

    phase 2 small molecule active

    1 trial

  4. Ladarixin, Placebo to match Ladarixin

    Dompe'

    Recent onset Type 1 Diabetes

    phase 2 small molecule active

    1 trial

  5. Reparixin, Placebo - Tablet for oral use

    Dompe'

    Acute Respiratory Distress Syndrome

    phase 2 small molecule active

    1 trial

  6. TACHIPIRINA 500 mg compresse, OKi 80 mg granulato per soluzione orale, KLS-GABA 40mg-17mg, KLS-GABA 80mg-34mg

    Dompe'

    Chronic low back pain

    phase 2 small molecule active

    1 trial

  7. Vehicle (Isocyclosporin A 0 mg/mL, 0%), Isocyclosporin A, TROPICAMIDE , SODIUM CHLORIDE , OXYBUPROCAINE

    Dompe'

    Atopic keratoconjunctivitis (AKC)

    phase 2 small molecule active

    1 trial

  8. Vehicle, Cenegermin

    Dompe'

    Subacute Moderate to Severe Traumatic Brain Injury (TBI)

    phase 2 small molecule active

    1 trial

  9. rhNGF New Lyo Formulation, OXYBUPROCAINE , SODIUM CHLORIDE , rhNGF New Lyo Formulation, The placebo consists of a lyophilized product packaged in 2R siliconized glass class I vials closed with a stopper and a flip off cap and administered after reconstitution with 2mL of diluent contained into a 2R glass class I vials closed with a stopper and a flip off cap. The diluent consists of DMSO, Sesame Extract 98%, Kollifor HS 0.15%, Sodium Chloride, Water For Injection. The product is reconstituted using an ada

    Dompe'

    Dry Eye

    phase 2 small molecule active

    1 trial

  10. A single and multiple ascending dose study of topical ladarixin ophthalmic solution in healthy volunteers

    Dompe'

    Ocular inflammatory conditions

    phase 1 other active

    1 trial

  11. Food effect and single- and multiple-ascending dose clinical trial of DF2755A in healthy participants

    Dompe'

    interstitial cystitis/bladder pain syndrome

    phase 1 other active

    1 trial

Frequently asked questions

What is Dompe'?

Dompe' (E24D8D7) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Dompe' sponsor?

We track 11 ClinicalTrials.gov-linked programs for Dompe', including Placebo (Vehicle) for investigational DFL24498, Isocyclosporin A, DEXAMETHASONE and 10 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Dompe' company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.